Boundless Bio Inc. (BOLD)
NASDAQ:BOLD
Top Page
Boundless Bio Inc.
(NASDAQ:BOLD)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.00
▼(-21.26% Downside)
Action:ReiteratedDate:03/09/26
The score is driven primarily by weak financial performance typical of an early-stage biotech (no revenue, sizable ongoing losses and negative free cash flow), despite some improvement versus 2024. Technicals also weigh on the score as the stock is below key moving averages with negative MACD. Valuation provides limited support because earnings are negative and no dividend yield is available.
Positive Factors
Proprietary ecDNA-focused platform
Boundless Bio’s explicit focus on ecDNA-driven oncogene amplification is a durable competitive angle: it targets a distinct biological driver of tumor evolution, supporting a differentiated discovery engine. A platform tied to a specific mechanism can create deep IP, higher entry barriers, and long-term program spillovers across tumor types.
Negative Factors
Pre-revenue with persistent cash burn
Boundless remains pre-revenue with sizable and persistent negative cash flow; TTM losses and negative free cash flow mean continued capital consumption. Over 2–6 months this structural cash burn requires either milestone execution to justify partnerships or additional financing, which can dilute shareholders or constrain strategic options if outcomes slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary ecDNA-focused platform
Boundless Bio’s explicit focus on ecDNA-driven oncogene amplification is a durable competitive angle: it targets a distinct biological driver of tumor evolution, supporting a differentiated discovery engine. A platform tied to a specific mechanism can create deep IP, higher entry barriers, and long-term program spillovers across tumor types.
Read all positive factors
Boundless Bio Inc. (BOLD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$24.20M
Dividend YieldN/A
Average Volume (3M)178.65K
Price to Earnings (P/E)―
Beta (1Y)1.74
Revenue GrowthN/A
EPS Growth-0.50%
CountryUS
Employees64
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.58
Shares Outstanding22,407,251
10 Day Avg. Volume162,533
30 Day Avg. Volume178,649
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.27
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap2.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-61.68
Enterprise Value/Ebitda-0.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-2.06
Revenue Forecast (FY)N/A
Boundless Bio Inc. Business Overview & Revenue Model
Company Description
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor o...
How the Company Makes Money
Boundless Bio Inc. generates revenue primarily through the development and commercialization of its proprietary therapies targeting ecDNA in cancer cells. The company may receive funding through partnerships, collaborations, and licensing agreemen...
Boundless Bio Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.25M | -1.09M | 0.00 | 0.00 | 0.00 |
| EBITDA | -62.30M | -64.28M | -53.84M | -45.53M | -24.62M |
| Net Income | -58.20M | -65.36M | -49.43M | -45.90M | -25.21M |
Balance Sheet | |||||
| Total Assets | 157.06M | 206.41M | 129.89M | 76.83M | 113.72M |
| Cash, Cash Equivalents and Short-Term Investments | 107.58M | 152.11M | 120.75M | 66.72M | 73.03M |
| Total Debt | 49.03M | 47.63M | 2.19M | 5.18M | 377.00K |
| Total Liabilities | 58.41M | 55.77M | 256.98M | 158.53M | 151.91M |
| Stockholders Equity | 98.65M | 150.64M | -127.08M | -81.70M | -38.19M |
Cash Flow | |||||
| Free Cash Flow | -47.21M | -63.38M | -47.49M | -40.66M | -25.28M |
| Operating Cash Flow | -46.66M | -60.84M | -46.85M | -39.60M | -23.25M |
| Investing Cash Flow | 37.80M | -26.10M | -38.26M | 16.13M | -59.28M |
| Financing Cash Flow | 141.00K | 89.82M | 97.90M | 126.00K | 105.53M |
Boundless Bio Inc. Technical Analysis
Negative
1.27
Price Trends
1.15
Negative
1.17
Negative
1.18
Negative
Market Momentum
-0.01
Positive
40.84
Neutral
22.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLD, the sentiment is Negative. The current price of 1.27 is above the 20-day moving average (MA) of 1.13, above the 50-day MA of 1.15, and above the 200-day MA of 1.18, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 40.84 is Neutral, neither overbought nor oversold. The STOCH value of 22.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLD.
Boundless Bio Inc. Risk Analysis
Boundless Bio Inc. disclosed 81 risk factors in its most recent earnings report. Boundless Bio Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Boundless Bio Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $259.27M | -0.60 | -118.95% | ― | ― | 31.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $7.62M | -1.49 | -92.74% | ― | 280.77% | 32.82% | |
44 Neutral | $24.51M | -0.43 | -70.57% | ― | -100.00% | -26.30% | |
42 Neutral | $24.20M | -0.46 | -49.73% | ― | ― | -0.50% | |
42 Neutral | $49.32M | -1.22 | -28.16% | ― | -55.88% | 6.14% | |
40 Underperform | $33.37M | -1.06 | 280.42% | ― | 121.74% | 24.75% |
* Healthcare Sector Average
BOLD
Boundless Bio Inc.
1.08
-0.12
-10.00%
PLUR
Pluri
3.32
-0.31
-8.54%
CLGN
Collplant Holdings
0.53
-1.87
-77.95%
ALXO
ALX Oncology Holdings
1.97
1.43
264.81%
ALGS
Aligos Therapeutics
7.97
2.92
57.82%
BRNS
Barinthus Biotherapeutics
0.60
-0.08
-11.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.